<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.98150</article-id><article-id pub-id-type="publisher-id">ACM-31770</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190800000_34583379.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  青春期多囊卵巢综合症的病因及治疗进展
  Etiology and Treatment Progress of Adolescent Polycystic Ovary Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>克敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>柳</surname><given-names>露</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>金</surname><given-names>天福</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>芹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明医科大学，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>08</issue><fpage>986</fpage><lpage>993</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    多囊卵巢综合症(polycystic ovary syndrome, PCOS)是妇科临床常见的内分泌疾病，发病率可达5%~10%。青春期PCOS病因尚未明确，通常表现为青春期人群月经紊乱、雄激素过多症和肥胖等。然而，证据表明青春期多囊卵巢综合征是遗传和环境因素相互作用所致。若不及时采取正确的诊断与治疗，会进一步导致青春期PCOS患者肥胖、多毛、痤疮、月经不调等，远期可能发生不孕及2型糖尿病、高血压、子宫内膜癌等，从而加重此类患者社会及心理负担。现将青春期PCOS的病因和治疗新进展予以综述，以期为临床治疗提供有力的依据。
    Polycystic ovary syndrome (PCOS) is a common endocrine disease in gynecology clinic, with an in-cidence of 5% - 10%. The etiology of adolescent PCOS is not yet clear, usually manifested as men-strual disorders, androgens and obesity in adolescents. However, evidence suggests that adolescent polycystic ovary syndrome is caused by the interaction of genetic and environmental factors. If the correct diagnosis and treatment are not taken in time, it will further lead to obesity, hirsutism, acne and irregular menstruation in adolescent PCOS patients. In the long run, infertility and type 2 diabetes mellitus, hypertension, endometrial cancer may occur, thus aggravating the social and psychological burden of such patients. This article reviews the etiology and treatment of adolescent PCOS in order to provide a strong basis for clinical treatment. 
  
 
</p></abstract><kwd-group><kwd>青春期多囊卵巢综合征，病因，非药物治疗，药物治疗, Adolescent Polycystic Ovary Syndrome</kwd><kwd> Etiology</kwd><kwd> Non-Drug Treatment</kwd><kwd> Drug Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>青春期多囊卵巢综合症的病因及治疗进展<sup> </sup></title><p>杨克敏，柳露<sup>*</sup>，金天福，李芹</p><p>昆明医科大学，云南 昆明</p><p><img src="//html.hanspub.org/file/14-1571008x1_hanspub.png" /></p><p>收稿日期：2019年7月29日；录用日期：2019年8月13日；发布日期：2019年8月20日</p><disp-formula id="hanspub.31770-formula13"><graphic xlink:href="//html.hanspub.org/file/14-1571008x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>多囊卵巢综合症(polycystic ovary syndrome, PCOS)是妇科临床常见的内分泌疾病，发病率可达5%~10%。青春期PCOS病因尚未明确，通常表现为青春期人群月经紊乱、雄激素过多症和肥胖等。然而，证据表明青春期多囊卵巢综合征是遗传和环境因素相互作用所致。若不及时采取正确的诊断与治疗，会进一步导致青春期PCOS患者肥胖、多毛、痤疮、月经不调等，远期可能发生不孕及2型糖尿病、高血压、子宫内膜癌等，从而加重此类患者社会及心理负担。现将青春期PCOS的病因和治疗新进展予以综述，以期为临床治疗提供有力的依据。</p><p>关键词 :青春期多囊卵巢综合征，病因，非药物治疗，药物治疗</p><disp-formula id="hanspub.31770-formula14"><graphic xlink:href="//html.hanspub.org/file/14-1571008x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1571008x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1571008x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 青春期PCOS的病因</title><p>目前尚未发现引起青春期PCOS的单一原因。相反，它被认为是与遗传和环境因素的相互作用有关的综合症 [<xref ref-type="bibr" rid="hanspub.31770-ref1">1</xref>]，主要与以下因素有关。</p><sec id="s3_1"><title>1.1. 胰岛素抵抗</title><p>胰岛素对人体雄激素的调节有重要作用，随着胰岛素水平的上升，性激素结合球蛋白(SHBG)在肝脏中的生成被抑制，从而导致SHBG下降，从而使游离雄激素升高 [<xref ref-type="bibr" rid="hanspub.31770-ref2">2</xref>]。多项研究 [<xref ref-type="bibr" rid="hanspub.31770-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref7">7</xref>] 表明，无论是否肥胖，PCOS人群中均存在胰岛素抵抗和高胰岛素血症，这是PCOS患者的关键发现。</p></sec><sec id="s3_2"><title>1.2. 肥胖</title><p>肥胖被认为是导致青春期PCOS的病因之一，与月经紊乱和雄激素浓度增加有关 [<xref ref-type="bibr" rid="hanspub.31770-ref8">8</xref>]。肥胖会促进胰岛素抵抗并加重PCOS患者中出现的雄激素过多症 [<xref ref-type="bibr" rid="hanspub.31770-ref1">1</xref>]。雄激素浓度增加与肥胖中性激素结合球蛋白减少部分相关。此外，肥胖可能导致雄激素过剩，因为脂肪组织含有几种类固醇生成酶，可将雄烯二酮转化为睾酮，将睾酮转化为更有效的雄激素–二氢睾酮(DHT)。在肥胖青春期女孩的多项研究中 [<xref ref-type="bibr" rid="hanspub.31770-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref11">11</xref>]，随着体重指数(BMI)的增加，游离睾酮浓度也会成比例上升。在正常体重的PCOS患者中，可能存在胰岛素抵抗，然而，当肥胖存在时，胰岛素抵抗力会明显增强 [<xref ref-type="bibr" rid="hanspub.31770-ref12">12</xref>]。此外，与肥胖但未进行PCOS诊断的患者相比，患有PCOS的肥胖青春期女孩表现出更显著的胰岛素抵抗和高胰岛素血症 [<xref ref-type="bibr" rid="hanspub.31770-ref8">8</xref>]。</p></sec><sec id="s3_3"><title>1.3. 遗传学</title><p>Wilroy等 [<xref ref-type="bibr" rid="hanspub.31770-ref13">13</xref>] 的研究显示PCOS具有家族聚集性，呈显性或多基因遗传模式。迄今为止，与PCOS的病理生理学有关的基因超过100个，特别是影响与性激素、细胞代谢和慢性炎症的生物合成和功能有关的基因。涉及与类固醇生成相关的几个关键基因，包括CYP17A1、CYP19、CYP21、HSD17B5和HSD17B6。性激素及其受体也参与其中。PCOS也是一种代谢紊乱性疾病，与2型糖尿病、高脂血症、肥胖和代谢综合征密切相关。相关代谢基因包括与胰岛素生物合成和功能相关的基因(INS (胰岛素基因)，INSR (胰岛素受体)，IRS1 (胰岛素受体底物1)，IRS2，IGF，PPAR-g和CAPN10)以及肥胖相关基因(FTO)。最后，考虑到PCOS与产生炎症的关系，还涉及与慢性炎症相关的基因，特别是炎性细胞因子，如肿瘤坏死因子-α(TNF)-α)，白细胞介素(IL)-6，IL-1A，IL-1B和纤溶酶原激活物抑制剂(PAI) [<xref ref-type="bibr" rid="hanspub.31770-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref15">15</xref>]。综上所述，与PCOS的病理生理学有关的基因多而复杂，但至今未发现诱发PCOS的特异基因，此领域有待进一步研究。</p></sec><sec id="s3_4"><title>1.4. 环境接触</title><p>环境暴露和生活方式因素与PCOS的发生有关。干扰内分泌的有关化学物质(EDCs)如双酚A(BPA)，以及晚期糖基化终产物(AGEs)等 [<xref ref-type="bibr" rid="hanspub.31770-ref16">16</xref>]，可能来源于食品包装以及工、农业所用原料、生活用品、医用塑料器具等，是PCOS发病的重要因素。接触时间至关重要，有证据 [<xref ref-type="bibr" rid="hanspub.31770-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref19">19</xref>] 表明在胎儿和幼儿时期最容易受到EDCs的不良影响。动物研究表明，在妊娠期处于高雄激素环境，更容易导致胎儿发生PCOS。与正常女性相比，PCOS女性的EDCs水平较高 [<xref ref-type="bibr" rid="hanspub.31770-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref21">21</xref>]。因此，成人长期暴露于EDCs也可能导致女性发生PCOS [<xref ref-type="bibr" rid="hanspub.31770-ref17">17</xref>]。</p></sec><sec id="s3_5"><title>1.5. LH受体与类固醇生成酶过度表达</title><p>一项来自PCOS患者的卵泡膜细胞的体外研究 [<xref ref-type="bibr" rid="hanspub.31770-ref22">22</xref>] 已经证明了LH受体和类固醇生成酶包括细胞色素P450c17、3b-HSD和17b-HSD有过度表达，与非PCOS患者的对比，PCOS患者17-OHP和睾酮等类固醇的产生增加。在青春期，下丘脑–垂体–卵巢轴逐渐成熟和LH循环水平逐渐增加。在患有PCOS倾向的青春期女性中这种增加更显著，进一步使雄激素的产生增加也更显著 [<xref ref-type="bibr" rid="hanspub.31770-ref2">2</xref>]。相应的，患有青春期PCOS的人群中分泌的GnRH和LH脉冲式释放的频率和振幅均增加，且LH与FSH的比值增也加 [<xref ref-type="bibr" rid="hanspub.31770-ref8">8</xref>]。</p></sec><sec id="s3_6"><title>1.6. 月经初潮年龄过小</title><p>一项研究显示青春期PCOS患者月经初潮年龄比非PCOS人群小，与体重及体重指数呈负相关，并且发现月经初潮年龄大是PCOS的保护因素 [<xref ref-type="bibr" rid="hanspub.31770-ref23">23</xref>]。因此，月经初潮年龄是青春期PCOS的影响因素之一。</p></sec><sec id="s3_7"><title>1.7. 出生时体重过低</title><p>研究表明低出生体重是PCOS发展的风险因素。一项回顾性研究 [<xref ref-type="bibr" rid="hanspub.31770-ref24">24</xref>] 结果显示，PCOS患者中低出生体重人群的比值是正常人群中低出生体重人群比值的5.34倍，95%置信区间(CI)为2.80~10.94，据此研究结果可认为与正常人群相比，PCOS人群的出生时体重显著降低，结果突出了出生体重因子对PCOS的重要性。另据报道 [<xref ref-type="bibr" rid="hanspub.31770-ref25">25</xref>]，在早产儿和出生低体重(LBW &lt; 1500 g)的受试者中，成年后对胰岛素敏感性降低，且表现出多毛症、痤疮、发生PCOS的比例较正常人群明显增高。</p></sec></sec><sec id="s4"><title>2. 治疗</title><p>青少年PCOS的治疗包括非药物治疗及药物治疗，具体方式是多样化的。主要包括以下方式。</p><sec id="s4_1"><title>2.1. 改变生活方式</title><p>大约50%的PCOS患者伴有超重或肥胖，而肥胖本身与2型糖尿病，高血压，心血管疾病和月经紊乱的风险增加有关 [<xref ref-type="bibr" rid="hanspub.31770-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref27">27</xref>]。生活方式改变包括主要是控制饮食和加强体育锻炼，上述方法已被证明能有效改善PCOS的相关症状 [<xref ref-type="bibr" rid="hanspub.31770-ref28">28</xref>]。体育锻炼作为治疗PCOS的干预措施，通常建议每周进行3次30至45分钟的剧烈运动 [<xref ref-type="bibr" rid="hanspub.31770-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref30">30</xref>]。Domecq, J. P.等 [<xref ref-type="bibr" rid="hanspub.31770-ref26">26</xref>] 对583名PCOS患者进行的荟萃分析显示，接受改变生活方式的患者的空腹血糖和胰岛素水平降低，其与接受二甲双胍治疗的患者疗效相当。另外，Orio, F.等 [<xref ref-type="bibr" rid="hanspub.31770-ref29">29</xref>] 对150名PCOS女性进行随机对照试验，为期6个月的运动训练后，PCOS女性的胰岛素敏感性指数得到改善。与正常人群相比，这些女性的子宫内膜厚度，血脂，心肺功能和月经周期均有改善。2013年，由内分泌学会指定的专家组制定的指南 [<xref ref-type="bibr" rid="hanspub.31770-ref28">28</xref>] 建议将改变生活方式、减轻体重，作为伴有超重或肥胖的青少年PCOS患者的一线治疗方法。但在患有PCOS的正常体重女性中，尚不清楚生活方式的改变是否会改善PCOS的症状 [<xref ref-type="bibr" rid="hanspub.31770-ref26">26</xref>]。前述指南 [<xref ref-type="bibr" rid="hanspub.31770-ref28">28</xref>] 提示，对于体重正常的PCOS患者，单独体育锻炼疗法可能是不够的。另一项随机对照试验 [<xref ref-type="bibr" rid="hanspub.31770-ref30">30</xref>] 对随机分入单一干预措施(包括二甲双胍，安慰剂，改变生活方式的方案或联合口服避孕药(COC))的43名12~18岁肥胖青少年女孩进行研究，结果显示仅通过改变生活方式，游离雄激素指数(FAI)降低59%，SHBG降低122%。一项前瞻性研究 [<xref ref-type="bibr" rid="hanspub.31770-ref31">31</xref>] 显示，在1年内完成生活方式干预的59名患者中，与没有体重减轻的患者相比体重减轻(BMI平均降低3.9 kg/m<sup>2</sup>)的患者闭经和月经稀发的患病率分别下降了42%和19%，且睾酮浓度降低、SHBG浓度增加。青少年人群在遵守饮食和锻炼方案方面还面临挑战应鼓励父母参与指导他们进行饮食，锻炼和行为等多方面的改变，保持健康的生活方式。但改变生活方式对于依从性差的患者疗效难以维持，且单纯改变生活方式对于月经紊乱的患者效果不佳，因此配合适当的药物治疗是必要的。</p></sec><sec id="s4_2"><title>2.2. 药物治疗</title><sec id="s4_2_1"><title>2.2.1. 复方激素避孕药(Compound hormonal contraceptives, CHCs)</title><p>CHCs是青春期PCOS的一线治疗药物，短效复方口服避孕药(COC)是其中最常用的一种 [<xref ref-type="bibr" rid="hanspub.31770-ref32">32</xref>]，COC为青春期PCOS人群带来多种益处。首先，COC具有抗雄激素作用。雌激素成分用于增加SHBG，其通过结合游离类固醇来降低生物可利用的睾酮，最终缓解高雄激素症状。其次，孕激素抑制LH水平，导致卵巢雄激素生成减少，孕激素还能抑制5a-还原酶活性 [<xref ref-type="bibr" rid="hanspub.31770-ref33">33</xref>]，从而减少睾酮向导致多毛症的二氢睾酮(DHT)的外周转化。在PCOS患者中运动疗法与COC比较的研究 [<xref ref-type="bibr" rid="hanspub.31770-ref29">29</xref>] 中，COC组的多毛症，血清游离睾酮和FAI显着降低(p &lt; 0.05)。另外，COC还可调整月经周期和保护子宫内膜 [<xref ref-type="bibr" rid="hanspub.31770-ref34">34</xref>]。PCOS通常是原发性闭经的原因，对于雄激素升高月经尚未初潮的青春期发育晚期阶段(即乳房发育 ≥ Tanner IV级)的女孩，建议启用COC进行治疗 [<xref ref-type="bibr" rid="hanspub.31770-ref28">28</xref>]。COC对于有性生活的青少年可以有避孕的作用。COC还可以改善患者的血脂，在短期内COC的雌激素成分可使HDL胆固醇增加，使总胆固醇和LDL-胆固醇降低 [<xref ref-type="bibr" rid="hanspub.31770-ref29">29</xref>]。但在采用COC作为PCOS的治疗策略之前必须排外禁忌症，如深静脉血栓栓塞、肺栓塞或有先兆的偏头痛等。</p></sec><sec id="s4_2_2"><title>2.2.2. 孕激素后半周期疗法</title><p>对于无严重高雄激素血症及代谢紊乱的PCOS人群可于月经后半周期口服孕激素调整月经周期。根据2018年多囊卵巢综合征中国诊疗指南 [<xref ref-type="bibr" rid="hanspub.31770-ref35">35</xref>]，周期性使用孕激素可以作为青春期PCOS患者的首选治疗，其对代谢影响小，且其对卵巢轴的功能不抑制或抑制较轻。</p></sec><sec id="s4_2_3"><title>2.2.3. 雌孕激素周期序惯疗法</title><p>少数雌激素水平较低、子宫内膜薄，单一孕激素治疗后子宫内膜无撤退性出血的PCOS人群可采用雌孕激素周期序惯疗法，对伴有低雌激素症状的青春期PCOS人群可作为首选治疗 [<xref ref-type="bibr" rid="hanspub.31770-ref35">35</xref>]。</p></sec><sec id="s4_2_4"><title>2.2.4. 二甲双胍</title><p>二甲双胍是一种治疗青少年PCOS的常用药物。在肥胖和非肥胖的PCOS青少年中大约18%~24%的人群伴有糖代谢异常，二甲双胍可降低肝脏葡萄糖的产生，增加外周组织对胰岛素的敏感性，使葡萄糖耐量升高和改善代谢综合征 [<xref ref-type="bibr" rid="hanspub.31770-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref37">37</xref>]。一项对照试验 [<xref ref-type="bibr" rid="hanspub.31770-ref38">38</xref>] 将79名肥胖青少年PCOS患者随机分为4组进行单一干预(干预措施包括二甲双胍，COC，改变生活方式和安慰剂)，结果显示，使用二甲双胍治疗人群甘油三酯和空腹血糖较安慰剂组有显着改善，此外，在青少年使用二甲双胍治疗还可以调整月经周期。对于有COC禁忌症的个体，尽管二甲双胍不会产生任何抗雄激素作用，也不会显着改善多毛症或痤疮 [<xref ref-type="bibr" rid="hanspub.31770-ref31">31</xref>]，但它仍是调整月经周期的优先选择。</p></sec><sec id="s4_2_5"><title>2.2.5. 螺内酯</title><p>螺内酯是另一种用于治疗PCOS和多毛症的辅助药物。该药作用机制是抑制雄激素的卵巢和肾上腺生物合成，直接竞争毛囊中的雄激素受体并抑制5α-还原酶活性，但对剂量依赖性较高且见效较慢 [<xref ref-type="bibr" rid="hanspub.31770-ref39">39</xref>]。目前还没有研究对青春期PCOS人群中的这种药物进行评估。然而，成人研究 [<xref ref-type="bibr" rid="hanspub.31770-ref40">40</xref>] 显示，对已服用二甲双胍的PCOS患者，加入低剂量螺内酯可降低DHEAS水平和减轻多毛症状。</p></sec><sec id="s4_2_6"><title>2.2.6. 中医治疗</title><p>由于青春期PCOS患者年龄偏小且暂没有生育要求，部分青春期PCOS人群及家长难以接受周期性激素治疗，针对这部分病人可考虑中医治疗。中医有研究资料 [<xref ref-type="bibr" rid="hanspub.31770-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.31770-ref42">42</xref>] 认为肾虚、血瘀、痰湿是本病的发病机制。李国珍等 [<xref ref-type="bibr" rid="hanspub.31770-ref43">43</xref>] 指出该病治疗上应补肾化痰，而补肾调经为治疗的关键，采用益肾活血化痰汤–五子衍宗丸合苍附导痰汤治疗PCOS取得较好疗效。褚娟红等 [<xref ref-type="bibr" rid="hanspub.31770-ref44">44</xref>] 运用补肾化痰活血法治疗PCOS的总有效率为90.0%，提示补肾、化痰祛瘀及疏肝理气的治疗也具有较好的治疗效果。但单用中药治疗周期较长，见效缓慢，因此需结合患者具体情况选择。</p></sec><sec id="s4_2_7"><title>2.2.7. 中西医结合治疗</title><p>目前中西医结合治疗青春期PCOS尚有很大的发展空间。在甘瑾等 [<xref ref-type="bibr" rid="hanspub.31770-ref45">45</xref>] 的一项予补肾祛瘀化痰方联合达英-35治疗多囊卵巢综合征的疗效研究中，将84例PCOS病患随机分成2组，即达英-35组(单用)，中西医结合组(达英-35 + 补肾祛瘀化痰方)，结果显示中西医结合组在减轻肥胖及降低体质指数、改善性激素指标与卵巢相关指标的疗效优于单用西药组。</p></sec><sec id="s4_2_8"><title>2.2.8. 手术治疗</title><p>青春期PCOS手术治疗主要是改善代谢的减肥手术。一项关于代谢手术对肥胖型PCOS的影响的荟萃分析 [<xref ref-type="bibr" rid="hanspub.31770-ref46">46</xref>]，纳入女性病人2274例，手术后月经紊乱及多毛症得到了明显改善，提示减肥手术可显著改善肥胖型PCOS的临床症状。但减肥手术适用于BMI 40 kg/m<sup>2</sup>以上的青春期肥胖患者，术式包括可调节胃束带术、胃旁路术、缩胃术 [<xref ref-type="bibr" rid="hanspub.31770-ref47">47</xref>]。虽然减肥手术的长期效果较好，并可预防与肥胖相关的并发症，但手术为有创操作，存在感染等手术并发症，且术后营养不良等问题尚未彻底解决，因此目前该治疗方案尚存在争议。</p></sec></sec></sec><sec id="s5"><title>3. 结论</title><p>综上所述，青春期PCOS的病因尚不明确，它是遗传、代谢和环境因素相互作用的结果。青春期PCOS的治疗是多模式的，改变生活方式适用于所有青春期PCOS患者，但需要长期坚持，对于依从性差的患者疗效难以维持，且不能达到调整月经周期的目的。口服避孕药可以调整月经周期，纠正高雄激素血症，远期可预防子宫内膜癌的发生，但口服避孕药有潜在风险，不适用于有血栓性疾病、心脑血管疾病高危因素及吸烟患者，用药期间需检测血脂变化。孕激素后半周期疗法、雌孕激素周期序惯疗法可以调整月经周期，但不能纠正高雄激素血症及代谢紊乱。二甲双胍可改善胰岛素抵抗，但部分人有胃肠道反应，严重者可发生肾功能损伤和乳酸性酸中毒，用药期间需定期复查肾功。螺内酯可改善高雄激素的临床表现，但不能调整月经周期及改善胰岛素抵抗情况。单用中药治疗疗程较长，见效较慢，中西医结合可有效改善月经紊乱及高雄激素血症，且见效快。手术治疗效果显著，但创伤大，存在手术并发症，需慎重选择。因此，非药物治疗是基础，药物治疗可根据患者具体症状给予不同的治疗方式，中西医结合治疗发展前景广阔。该病病因复杂且尚无根治的办法，明确青春期PCOS人群发病原因和确定最佳的治疗方案以及根治此病的方法尚需进行更深入的研究。</p></sec><sec id="s6"><title>文章引用</title><p>杨克敏,柳 露,金天福,李 芹. 青春期多囊卵巢综合症的病因及治疗进展Etiology and Treatment Progress of Adolescent Polycystic Ovary Syndrome[J]. 临床医学进展, 2019, 09(08): 986-993. https://doi.org/10.12677/ACM.2019.98150</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31770-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rosenfield, R.L. and Ehrmann, D.A. (2016) The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 37, 467-520.  
&lt;br&gt;https://doi.org/10.1210/er.2015-1104</mixed-citation></ref><ref id="hanspub.31770-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Franks, S. (2008) Polycystic Ovary Syndrome in Adolescents. International Journal of Obesity, 32, 1035.  
&lt;br&gt;https://doi.org/10.1038/ijo.2008.61</mixed-citation></ref><ref id="hanspub.31770-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Burghen, G.A., Givens, J.R. and Kitabchi, A.E. (1980) Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease. The Journal of Clinical Endocrinology &amp; Metabolism, 50, 113-116.  
&lt;br&gt;https://doi.org/10.1210/jcem-50-1-113</mixed-citation></ref><ref id="hanspub.31770-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chang, R.J., Nakamura, R.M., Judd, H.L., et al. (1983) Insulin Resistance in Nonobese Patients with Polycystic Ovarian Disease. The Journal of Clinical Endocrinology &amp; Metabolism, 57, 356-359.  
&lt;br&gt;https://doi.org/10.1210/jcem-57-2-356</mixed-citation></ref><ref id="hanspub.31770-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dunaif, A., Segal, K.R., Shelley, D.R., et al. (1992) Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome. Diabetes, 41, 1257-1266. &lt;br&gt;https://doi.org/10.2337/diab.41.10.1257</mixed-citation></ref><ref id="hanspub.31770-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ehrmann, D.A., Sturis, J., Byrne, M.M., et al. (1995) Insulin Secretory Defects in Polycystic Ovary Syndrome. Relationship to Insulin Sensitivity and Family History of Non-Insulin-Dependent Diabetes Mellitus. The Journal of Clinical Investigation, 96, 520-527. &lt;br&gt;https://doi.org/10.1172/JCI118064</mixed-citation></ref><ref id="hanspub.31770-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nestler, J.E. (1997) Insulin Regulation of Human Ovarian Androgens. Human Reproduction, 12, 53-62.  
&lt;br&gt;https://doi.org/10.1093/humrep/12.suppl_1.53</mixed-citation></ref><ref id="hanspub.31770-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Anderson, A.D., Solorzano, C.M.B. and McCartney, C.R. (2014) Childhood Obesity and Its Impact on the Development of Adolescent PCOS. Seminars in Reproductive Medicine, 32, 202-213. &lt;br&gt;https://doi.org/10.1055/s-0034-1371092</mixed-citation></ref><ref id="hanspub.31770-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">McCartney, C.R., Blank, S.K., Prendergast, K.A., et al. (2006) Obesity and Sex Steroid Changes across Puberty: Evidence for Marked Hyperandrogenemia in Pre- and Early Pubertal Obese Girls. The Journal of Clinical Endocrinology &amp; Metabolism, 92, 430-436. &lt;br&gt;https://doi.org/10.1210/jc.2006-2002</mixed-citation></ref><ref id="hanspub.31770-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">McCartney, C.R., Prendergast, K.A., Chhabra, S., et al. (2006) The Association of Obesity and Hyperandrogenemia during the Pubertal Transition in Girls: Obesity as a Potential Factor in the Genesis of Postpubertal Hyperandrogenism. The Journal of Clinical Endocrinology &amp; Metabolism, 91, 1714-1722. &lt;br&gt;https://doi.org/10.1210/jc.2005-1852</mixed-citation></ref><ref id="hanspub.31770-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Reinehr, T., de Sousa, G., Roth, C.L., et al. (2005) Androgens before and after Weight Loss in Obese Children. The Journal of Clinical Endocrinology &amp; Metabolism, 90, 5588-5595. &lt;br&gt;https://doi.org/10.1210/jc.2005-0438</mixed-citation></ref><ref id="hanspub.31770-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Rojas, J., Chávez, M., Olivar, L., et al. (2014) Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine, 2014, Article ID: 719050.  
&lt;br&gt;https://doi.org/10.1155/2014/719050</mixed-citation></ref><ref id="hanspub.31770-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wilroy, R.S., Givens, J.R., Wiser, W.L., et al. (1975) Hyperthecosis, an Inheritance Form of Polycystic Ovary. I. Clinical and Histologic Features. The Journal of Clinical Endocrinology &amp; Metabolism, 22, 326-328.</mixed-citation></ref><ref id="hanspub.31770-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H., Lv, Y., Li, L., et al. (2016) Genetic Studies on Polycystic Ovary Syndrome. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology, 37, 56-65. &lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2016.04.002</mixed-citation></ref><ref id="hanspub.31770-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Azziz, R., Carmina, E., Chen, Z., et al. (2016) Polycystic Ovary Syndrome. Nature Reviews Disease Primers, 2, 16057.  
&lt;br&gt;https://doi.org/10.1038/nrdp.2016.58</mixed-citation></ref><ref id="hanspub.31770-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Rutkowska, A.Z. and Diamanti-Kandarakis, E. (2016) Polycystic Ovary Syndrome and Environmental Toxins. Fertility and Sterility, 106, 948-958. &lt;br&gt;https://doi.org/10.1016/j.fertnstert.2016.08.031</mixed-citation></ref><ref id="hanspub.31770-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., et al. (2009) Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. Endocrine Reviews, 30, 293-342. &lt;br&gt;https://doi.org/10.1210/er.2009-0002</mixed-citation></ref><ref id="hanspub.31770-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bolognesi, C., Castle, L., Cravedi, J.P., et al. (2015) Scientific Opinion on the Risks to Public Health Related to the Presence of Bisphenol A (BPA) in Foodstuffs: Executive Summary. EFSA Journal, 13, 3978.</mixed-citation></ref><ref id="hanspub.31770-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Testai, E. (2016) The Safety of Medical Devices Containing DEHP Plasticized PVC or Other Plasticizers on Neonates and Other Groups Possibly at Risk (2015 Update). Regulatory Toxicology and Pharmacology: RTP, 76, 209.  
&lt;br&gt;https://doi.org/10.1016/j.yrtph.2016.01.013</mixed-citation></ref><ref id="hanspub.31770-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Takeuchi, T., Tsutsumi, O., Ikezuki, Y., et al. (2004) Positive Relationship between Androgen and the Endocrine Disruptor, Bisphenol A, in Normal Women and Women with Ovarian Dysfunction. Endocrine Journal, 51, 165-169.  
&lt;br&gt;https://doi.org/10.1507/endocrj.51.165</mixed-citation></ref><ref id="hanspub.31770-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Diamanti-Kandarakis, E., Katsikis, I., Piperi, C., et al. (2008) Increased Serum Advanced Glycation End-Products Is a Distinct Finding in Lean Women with Polycystic Ovary Syndrome (PCOS). Clinical Endocrinology, 69, 634-641.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2265.2008.03247.x</mixed-citation></ref><ref id="hanspub.31770-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Nelson, V.L., Legro, R.S., Strauss III, J.F., et al. (1999) Augmented Androgen Production Is a Stable Steroidogenic Phenotype of Propagated Theca Cells from Polycystic Ovaries. Molecular Endocrinology, 13, 946-957.  
&lt;br&gt;https://doi.org/10.1210/mend.13.6.0311</mixed-citation></ref><ref id="hanspub.31770-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">de Faria, F.R., Gusmão, L.S., de Faria, E.R., et al. (2013) Polycystic Ovary Syndrome and Intervening Factors in Adolescents from 15 to 18 Years Old. Revista da Associação Médica Brasileira (English Edition), 59, 341-346.  
&lt;br&gt;https://doi.org/10.1016/S2255-4823(13)70485-5</mixed-citation></ref><ref id="hanspub.31770-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Stracquadanio, M. and Ciotta, L. (2017) Low Birth-Weight Is a PCOS Risk Factor for Southern-Italian Women. Gynecological Endocrinology, 33, 373-377. &lt;br&gt;https://doi.org/10.1080/09513590.2017.1283487</mixed-citation></ref><ref id="hanspub.31770-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Pandolfi, C., Zugaro, A., Lattanzio, F., et al. (2008) Low Birth Weight and Later Development of Insulin Resistance and Biochemical/Clinical Features of Polycystic Ovary Syndrome. Metabolism, 57, 999-1004.  
&lt;br&gt;https://doi.org/10.1016/j.metabol.2008.02.018</mixed-citation></ref><ref id="hanspub.31770-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Domecq, J.P., Prutsky, G., Mullan, R.J., et al. (2013) Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology &amp; Metabolism, 98, 4655-4663.  
&lt;br&gt;https://doi.org/10.1210/jc.2013-2385</mixed-citation></ref><ref id="hanspub.31770-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Cattrall, F.R. and Healy, D.L. (2004) Long-Term Metabolic, Cardiovascular and Neoplastic Risks with Polycystic Ovary Syndrome. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology, 18, 803-812.  
&lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2004.05.005</mixed-citation></ref><ref id="hanspub.31770-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. (2013) Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology &amp; Metabolism, 98, 4565-4592.  
&lt;br&gt;https://doi.org/10.1210/jc.2013-2350</mixed-citation></ref><ref id="hanspub.31770-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Orio, F., Muscogiuri, G., Giallauria, F., et al. (2016) Oral Contraceptives versus Physical Exercise on Cardiovascular and Metabolic Risk Factors in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Clinical Endocrinology, 85, 764-771. &lt;br&gt;https://doi.org/10.1111/cen.13112</mixed-citation></ref><ref id="hanspub.31770-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hoeger, K., Davidson, K., Kochman, L., et al. (2008) The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials. The Journal of Clinical Endocrinology &amp; Metabolism, 93, 4299-4306.  
&lt;br&gt;https://doi.org/10.1210/jc.2008-0461</mixed-citation></ref><ref id="hanspub.31770-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Lass, N., Kleber, M., Winkel, K., et al. (2011) Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls. The Journal of Clinical Endocrinology &amp; Metabolism, 96, 3533-3540. &lt;br&gt;https://doi.org/10.1210/jc.2011-1609</mixed-citation></ref><ref id="hanspub.31770-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Powers, B.J., Brown, G., Williams, R.W., et al. (2015) Medical Eligibility Criteria for Contraceptive Use. World Health Organization, 87, 276.</mixed-citation></ref><ref id="hanspub.31770-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Cassidenti, D.L., Paulson, R.J., Serafini, P., et al. (1991) Effects of Sex Steroids on Skin 5 Alpha-Reductase Activity in Vitro. Obstetrics and Gynecology, 78, 103-107.</mixed-citation></ref><ref id="hanspub.31770-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Gerlinger, C. and Heithecker, R. (2002) The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea. Cutis, 69, 2-15.</mixed-citation></ref><ref id="hanspub.31770-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国治疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6.</mixed-citation></ref><ref id="hanspub.31770-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Natali, A. and Ferrannini, E. (2006) Effects of Metformin and Thiazolidinediones on Suppression of Hepatic Glucose Production and Stimulation of Glucose Uptake in Type 2 Diabetes: A Systematic Review. Diabetologia, 49, 434-441.  
&lt;br&gt;https://doi.org/10.1007/s00125-006-0141-7</mixed-citation></ref><ref id="hanspub.31770-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Foretz, M., Guigas, B., Bertrand, L., et al. (2014) Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 20, 953-966. &lt;br&gt;https://doi.org/10.1016/j.cmet.2014.09.018</mixed-citation></ref><ref id="hanspub.31770-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Gooding, H.C., Milliren, C., Paul, M.S., et al. (2014) Diagnosing Dysglycemia in Adolescents with Polycystic Ovary Syndrome. Journal of Adolescent Health, 55, 79-84. &lt;br&gt;https://doi.org/10.1016/j.jadohealth.2013.12.020</mixed-citation></ref><ref id="hanspub.31770-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Speroff, L. and Fritz, M.A. (2005) Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams &amp; Wilkins, Philadelphia.</mixed-citation></ref><ref id="hanspub.31770-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Mazza, A., Fruci, B., Guzzi, P., et al. (2014) In PCOS Patients the Addition of Low-Dose Spironolactone Induces a More Marked Reduction of Clinical and Biochemical Hyperandrogenism than Metformin Alone. Nutrition, Metabolism and Cardiovascular Diseases, 24, 132-139. &lt;br&gt;https://doi.org/10.1016/j.numecd.2013.04.016</mixed-citation></ref><ref id="hanspub.31770-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">杨雪萍. 多囊卵巢综合征与肝肾相关说[J]. 河南中医, 2012, 32(2): 144-145.</mixed-citation></ref><ref id="hanspub.31770-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">张宁, 刘家义. 痰湿型多囊卵巢综合征临床及内分泌特征分析[J]. 辽宁中医药大学学报, 2010, 12(7): 27-29.</mixed-citation></ref><ref id="hanspub.31770-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">李国珍, 阿依努尔. 补肾活血化痰法治疗多囊卵巢综合征56例[J]. 新疆中医药, 2014, 32(2): 16-18.</mixed-citation></ref><ref id="hanspub.31770-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">褚娟红, 吴桂珠. 补肾化痰活血法治疗多囊卵巢综合症30例疗效观察[J]. 现代实用医学, 2014, 26(5): 619-620.</mixed-citation></ref><ref id="hanspub.31770-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">甘瑾. 补肾祛瘀化痰方联合达英——35治疗多囊卵巢综合征的疗效研究[J]. 中医药学报, 2017, 45(5): 85-87.</mixed-citation></ref><ref id="hanspub.31770-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">刘欢妹, 刘宇萌, 魏丹, 孟化. 代谢手术治疗肥胖型多囊卵巢综合征的meta分析[J]. 内蒙古医科大学学报, 2019, 41(2): 139-143.</mixed-citation></ref><ref id="hanspub.31770-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Fitzgerald, D.A. and Baur, L. (2014) Bariatric Surgery for Severely Obese Adolescents. Paediatric Respiratory Reviews, 15, 227-230. &lt;br&gt;https://doi.org/10.1016/j.prrv.2014.06.001</mixed-citation></ref></ref-list></back></article>